Perflutren
Contrast Agent for Ultrasound Imaging — VARIOUS
Also known as: luminity, octafluoropropane, perfluoropropane
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Perflutren is an onp drug in the Contrast Agent for Ultrasound Imaging class catalogued in DrugCentral. It was first approved by the FDA in 2001. Its mechanism of action is classified as Ultrasound Contrast Activity. Recorded indications include Echocardiography.
- Approval status: onp (first approved 2001 by the FDA).
- Drug class: Contrast Agent for Ultrasound Imaging.
- Mechanism of action: Ultrasound Contrast Activity.
- Indications: Echocardiography.
- ATC code: V08DA01 (Ultrasound contrast media).
- Molecular formula: C3F8; molecular weight 188.02 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (1)
- Echocardiography
Mechanism & targets
| Mechanism of action (MoA) | Ultrasound Contrast Activity |
|---|---|
| Established pharmacologic class | Contrast Agent for Ultrasound Imaging |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 2001-07-31 | FDA | — | LANTHEUS MEDCL |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
V08DA01 | VARIOUS › CONTRAST MEDIA › ULTRASOUND CONTRAST MEDIA › Ultrasound contrast media |
V08DA04 | VARIOUS › CONTRAST MEDIA › ULTRASOUND CONTRAST MEDIA › Ultrasound contrast media |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Back pain | 2067.8 |
| Muscle spasms | 478.4 |
| Flushing | 342.1 |
| Neck pain | 209.3 |
| Contrast media reaction | 197.4 |
| Dyspnoea | 167.6 |
| Chest pain | 143.0 |
| Pain in extremity | 142.6 |
| Anaphylactic reaction | 135.5 |
| Urticaria | 122.0 |
| Unresponsive to stimuli | 108.9 |
| Flank pain | 102.1 |
Chemical structure
Full physicochemical, ADMET and 3D-structure analysis of Perflutren is on its molecule page.
| Molecular formula | C3F8 |
|---|---|
| Molecular weight | 188.02 g/mol |
| CAS number | 76-19-7 |
| InChIKey | QYSGYZVSCZSLHT-UHFFFAOYSA-N |
| PubChem CID | 6432 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Perflutren used for?
DrugCentral lists the following indications for Perflutren: Echocardiography.
How does Perflutren work?
Perflutren is classified as Ultrasound Contrast Activity.
When was Perflutren first approved?
Perflutren was first approved by the FDA in 2001.
What drug class does Perflutren belong to?
Perflutren is in the Contrast Agent for Ultrasound Imaging class.
What is the chemical formula of Perflutren?
Perflutren has the molecular formula C3F8 and a molecular weight of 188.02 g/mol.
Browse: all drugs starting with P · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 2104 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL1663 — compound record and bioactivity
- PubChem CID 6432 — chemical identifiers
- DrugBank DB00556 — drug record
- FDA UNII CK0N3WH0SR — substance identity
- DailyMed: FDA labels for Perflutren — current prescribing information (label search)
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.